More blood pressure medication recalled for small amounts of possible cancer-causing substance

According to the U.S. Food and Drug Administration , more blood pressure medications were voluntarily recalled March 15 due to "a possible process impurity or contaminant in an active pharmaceutical ingredient."

Missouri pharmaceutical company, Legacy Pharmaceutical Packaging, LLC, is recalling 40 repackaged lots of Losartan Potassium Tablets USP in 25-mg, 50-mg and 100-mg doses, the FDA press release stated.

Legacy's recall comes after another pharmaceutical company, Camber Pharmaceuticals, issued a voluntary recall on Losartan Tablets, USP.

The FDA said trace amounts of N-Nitroso N-Methyl 4-aminobutyric acid (NMBA), a potential human carcinogen, were detected in the medication.

Legacy says they have not received any reports of adverse events related to the recall, the FDA said.

The affected Losartan Potassium lots are:

You can find what other Losartan prodcuts are under recall here and a list of all drug recalls can be found on the FDA website.